TGFA and central nervous system cancer: To assess therapeutic benefits or unintended effects of TGFA as a glioma drug target and evaluate off-target pleiotropy beyond MR–Egger intercept findings, we performed gene-level PheWAS using 17,361 binary and 1,419 quantitative traits from the AstraZeneca PheWAS Portal (31).